• About Us
    • Who We Are
    • Our History
    • Mission & Values
    • Our Leadership
    • Why Choose Jost
  • Products
    • Ammonium
    • Calcium
    • Copper
    • Iron
    • Magnesium
    • Manganese
    • Potassium
    • Sodium
    • Strontium
    • Zinc
    • Ultra Pure Minerals (Low Heavy Metals)
    • JOSTCOTE® Microencapsulated Products
    • New Products
    • Custom Products
  • Our Expertise
    • cGMP Manufacturing
    • Quality
    • Research & Development
    • Customer Service
  • Markets
    • Nutritional
    • Pharmaceutical / Biotech
    • Specialty
  • Media
    • News
    • Events
    • Videos
  • Technical Info
    • Documents
    • Links
  • Contact Us
    • Sales & Customer Service
    • Locations
  • Careers
Jost Chemical Co.
  • FAQ
  • Download Catalog
  • 314-428-4300
  • About Us
    • Who We Are
    • Our History
    • Mission & Values
    • Our Leadership
    • Why Choose Jost
  • Products
    • Ammonium
    • Calcium
    • Copper
    • Iron
    • Magnesium
    • Manganese
    • Potassium
    • Sodium
    • Strontium
    • Zinc
    • Ultra Pure Minerals (Low Heavy Metals)
    • JOSTCOTE® Microencapsulated Products
    • New Products
    • Custom Products
  • Our Expertise
    • cGMP Manufacturing
    • Quality
    • Research & Development
    • Customer Service
  • Markets
    • Nutritional
    • Pharmaceutical / Biotech
    • Specialty
  • Media
    • News
    • Events
    • Videos
  • Technical Info
    • Documents
    • Links
  • Contact Us
    • Sales & Customer Service
    • Locations
  • Careers
Home › Related Articles › Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium magnesium citrate: a feasibility study.
Journal of Nephrology. 2019 Feb

Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium magnesium citrate: a feasibility study.

Abstract:

AIMS: Cardiovascular (CV) complications are common in chronic kidney disease (CKD). Numerous metabolic disturbances including hyperphosphatemia, high circulating calciprotein particles (CPP), hyperparathyroidism, metabolic acidosis, and magnesium deficiency are associated with, and likely pathogenic for CV complications in CKD. The goal of this feasibility study was to determine whether effervescent calcium magnesium citrate (EffCaMgCit) ameliorates the aforementioned pathogenic intermediates.

METHODS: Nine patients with Stage 3 and nine patients with Stage 5D CKD underwent a randomized crossover study, where they took EffCaMgCit three times daily for 7 days in one phase, and a conventional phosphorus binder calcium acetate (CaAc) three times daily for 7 days in the other phase. Two-hour postprandial blood samples were obtained on the day before and on the 7th day of treatment.

RESULTS: In Stage 5D CKD, EffCaMgCit significantly increased T50 (half time for conversion of primary to secondary CPP) from baseline by 63% (P = 0.013), coincident with statistically non-significant declines in serum phosphorus by 25% and in saturation of octacalcium phosphate by 35%; CaAc did not change T50. In Stage 3 CKD, neither EffCaMgCit nor CaAc altered T50. With EffCaMgCit, a significant increase in plasma citrate was accompanied by statistically non-significant increase in serum Mg and phosphate. CaAc was without effect in any of these parameters in Stage 3 CKD. In both Stages 3 and 5D, both drugs significantly reduced serum parathyroid hormone. Only EffCaMgCit significantly increased serum bicarbonate by 3 mM (P = 0.015) in Stage 5D.

CONCLUSIONS: In Stage 5D, EffCaMgCit inhibited formation of CPP, suppressed PTH, and conferred magnesium and alkali loads. These effects were unique, since they were not observed with CaAc. In Stage 3 CKD, neither of the regimens have any effect. These metabolic changes suggest that EffCaMgCit might be useful in protecting against cardiovascular complications of CKD by ameliorating pathobiologic intermediates.

PMID 30465137  /  Quiñones H, Hamdi T, Sakhaee K, Pasch A, Moe OW, Pak CYC

Related Products
  • Magnesium Citrate Tribasic Anhydrous EP Granular – Product Code 2550
  • Magnesium Citrate Tribasic Anhydrous USP Granular – Product Code 2549
  • Magnesium Citrate Tribasic Hydrate USP Ultrafine Powder – Product Code 2535
  • Magnesium Citrate Tribasic Hydrate USP Powder – Product Code 2544
  • Magnesium Citrate Tribasic Hydrate USP Fine Granular – Product Code 2542
  • News
    • Company News
    • Product Development
    • Industry News
    • Awards
  • Events
  • Videos
  • Documents

Learn about new Jost products and events.
subscribe

  • Who We Are
  • Products
  • Documents
  • News
  • Contact
  • Careers
  • Spanish
  • German
  • French

Follow Us

  • linkedin
  • facebook

Jost Chemical Co.
(The Americas and Asia)
8150 Lackland
St. Louis, MO 63114
Tel: +1 314 428 4300
Fax: +1 314 428 4366
customer.service@jostchemical.comcustomer.service@jostchemical.com

Jost Chemical Europe SPRL
(Europe, Middle East and Africa)
Rue du Bois Portal 30/1-3
5300 Andenne, Belgium
Tel: +32 85 552 655
Fax: +32 85 552 654
customer.service@jostchemical.cominfo@josteurope.com

Sitemap     Privacy Policy     Cookies     Terms of Use

Copyright © 1995-2017 Jost Chemical Co. All rights reserved.